Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. 2017

Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.

Chronic myelomonocytic leukemia is characterized by persistent absolute monocytosis (≥1 × 109/l) in the peripheral blood and dysplasia in ≥1 lineages. In the absence of dysplasia, an acquired clonal genetic abnormality is required or causes for reactive monocytosis have to be excluded. Oligomonocytic chronic myelomonocytic leukemia showing increased monocytes but no absolute monocytosis in the peripheral blood occurs occasionally. These cases are likely classified as myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm, unclassifiable. A subset eventually develop overt chronic myelomonocytic leukemia. Better characterization of oligomonocytic chronic myelomonocytic leukemia is essential since the distinction between chronic myelomonocytic leukemia and myelodysplastic syndrome is clinically relevant. We identified 44 cases of oligomonocytic chronic myelomonocytic leukemia (≥10% peripheral blood monocytes with absolute monocyte count of 0.5-1 × 109/l) and 28 consecutive chronic myelomonocytic leukemia controls. Clinicopathologic features were compared and mutation analysis was performed. Oligomonocytic chronic myelomonocytic leukemia patients were significantly younger (median age of 65 vs 72). They had lower WBC and absolute neutrophil count, while the monocyte percentage, hemoglobin and platelet counts were similar in the two groups. The myeloid to erythroid ratio was predominantly decreased or normal, compared with the characteristic increase in chronic myelomonocytic leukemia (P=0.006). 38% of patients progressed to overt chronic myelomonocytic leukemia (median: 12 months). The overall percentage of mutations was significantly lower in oligomonocytic chronic myelomonocytic leukemia. However, the most frequent mutations in both groups were the 'signature' chronic myelomonocytic leukemia mutations in ASXL1, TET2 and SRSF2. Mutations in CBL were found exclusively in overt chronic myelomonocytic leukemia. In conclusion, we demonstrate clinical and genetic similarities between overt chronic myelomonocytic leukemia and oligomonocytic chronic myelomonocytic leukemia. The findings suggest that at least a subset of oligomonocytic chronic myelomonocytic leukemia represents early phase 'dysplastic type' chronic myelomonocytic leukemia.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional

Related Publications

Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
May 2021, Blood cells, molecules & diseases,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
October 2020, Blood advances,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
February 2021, American journal of hematology,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
October 2013, Leukemia & lymphoma,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
January 2021, Journal of clinical laboratory analysis,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
April 2024, International journal of laboratory hematology,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
January 2022, Leukemia research reports,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
January 2019, Annals of hematology,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
December 2022, Leukemia,
Julia T Geyer, and Wayne Tam, and Yen-Chun Liu, and Zhengming Chen, and Sa A Wang, and Carlos Bueso-Ramos, and Jean Oak, and Daniel A Arber, and Eric Hsi, and Heesun J Rogers, and Katherine Levinson, and Adam Bagg, and Duane C Hassane, and Robert P Hasserjian, and Attilio Orazi
June 2021, Current hematologic malignancy reports,
Copied contents to your clipboard!